MiraDx

PROSTOX ultra and PROSTOX CFRT—genetic assays to help prostate cancer patients avoid radiation toxicity. Recent studies have shown that miRNA-associated germline single nucleotide polymorphisms (mirSNPs) can determine a patient's risk of developing late genitourinary (GU) toxicity from radiation therapy. These mirSNP signatures, PROSTOX, can predict the risk of late grade ≥2 GU toxicity following stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CFRT). Furthermore, these findings have been independently validated in both a post-operative SBRT study and a clinical utility study. With PROSTOX testing, clinicians can choose the most appropriate radiation therapy approach, minimizing the risk of late radiation toxicity. #miRNA #mirSNPs #RadiationTherapy #GUtoxicity #PROSTOX #PersonalizedMedicine #OncologyResearch Link: https://lnkd.in/gc-mSsrY

“[PROSTOX] is worth it to avoid having a treatment that could cause side effects for the rest of your life." - Don Tate, prostate cancer patient. When Don Tate received borderline-high results from his prostate-specific antigen (PSA) test, his primary physician strongly recommended he consult a urologist to explore the possibility of prostate cancer. However, despite ongoing evaluations, no obvious diagnosis emerged. Over the next three years, Don faced a series of conflicting opinions, leaving him uncertain whether treatment was necessary. Amid this confusion, Don found reassurance in a call from Dr. Weidhaas, a radiation oncologist at UCLA Medical Center and MiraDx’s founder, to discuss his PROSTOX ultra test results. The test indicated an increased risk of long-term side effects from stereotactic body radiotherapy (SBRT), which could potentially develop three months or more after treatment. #ProstateHealth #CancerAwareness #PatientJourney #Urology #RadiationOncology #PSATesting #MiraDx Read more about Don’s story: https://lnkd.in/gBADxrnN Physicians can learn more about PROSTOX at: https://miradx.com/prostox

PROSTOX is a biomarker that predicts late grade ≥ 2 genitourinary (GU) toxicity following stereotactic body radiotherapy (SBRT) for patients with an intact prostate. In an analysis of the SCIMITAR phase II clinical trial, PROSTOX was able to identify patients at a higher risk of experiencing late grade ≥ 2 GU toxicity after post-prostatectomy SBRT. The results show that patients considered high-risk by PROSTOX were more likely to experience severe toxicity, while those identified as low-risk had a significantly lower chance. Although post-prostatectomy SBRT is in the clinical trial study phase, this data suggests that PROSTOX could be useful for predicting toxicity in this setting. #PROSTOX #Biomarkers #GenitourinaryToxicity #StereotacticBodyRadiotherapy #SBRT #ProstateCancer #OncologyResearch Link: https://lnkd.in/gnMAReZy

The average risk of experiencing significant urinary toxicity after radiation therapy for prostate cancer is 15% or higher, regardless of the radiation fractionation method used. Both stereotactic body radiotherapy (SBRT) and conventionally fractionated radiotherapy (CFRT) are effective treatments for prostate cancer. SBRT delivers higher doses in fewer sessions, while CFRT provides smaller doses over several weeks. While small and large radiation fraction treatments have similar levels of toxicity and cure rates, the genetic risks that come with each may differ. Understanding these differences is important for making informed treatment decisions. Before starting SBRT or CFRT, PROSTOX can predict the risk of a patient developing late-grade (grade ≥2) genitourinary toxicity (urinary toxicity). Based on the prediction, patients receive either a high-risk or low-risk score, which can guide the selection of the safest treatment plan. ?? PROSTOX ultra is for patients considering SBRT. ?? PROSTOX CFRT is for patients considering CFRT. Having a high-risk result for one test does not mean a patient will have a high risk for another radiation fractionation treatment. #RadiationTherapy #ProstateCancer #Oncology #PrecisionMedicine #ToxicityManagement #PROSTOX #SBRT

#MakingADifference Why Atlas likes working at MiraDX... #GeneticTesting #BiomarkerTesting #PrecisionMedicine #PersonalizedMedicine #Cancer

SBRT is a highly effective treatment for prostate cancer -- however, genitourinary (GU) toxicity may occur after treatment, which can have a significant impact on a patient's quality of life. In the MIRAGE randomized clinical trial, PROSTOX was shown to accurately predict late Grade ≥ 2 GU toxicity after SBRT. Knowing if a patient is at a low or high risk of GU toxicity can help determine the safest course of radiation therapy. See the poster: https://lnkd.in/gnJf5BNK #ProstateCancer #RadiationTherapy #Cancer #Oncology #Biomarkers #PersonalizedMedicine #PROSTOX

Why MiraDX? Our VP of Engineering, Trinity M., explains why she joined the team. ?????????? Learn more about our mission: https://miradx.com/about #CompanyCulture #GeneticTesting #BiomarkerTesting #PrecisionMedicine #PersonalizedMedicine #HealthcareInnovation

Important steps towards further personalizing radiation therapy, considering late toxicity as an important component of outcome.

This year, approximately 300,000 men in the U.S. received a prostate cancer diagnosis, bringing the total to over 3.3 million cases. Nearly half of men diagnosed with localized prostate cancer will undergo radiation therapy, of which 15% will experience late-grade GU toxicity. Understanding an individual’s response to treatment is paramount. PROSTOX marks a pivotal step forward, enabling healthcare providers to assess the risk of adverse reactions and formulate suitable treatment plans that prioritize patient safety in prostate cancer management. Learn more: https://miradx.com/prostox #ProstateCancer #RadiationTherapy #Cancer #Oncology #Biomarkers #PersonalizedMedicine #PROSTOX

Today the Nobel Prize in Physiology or Medicine 2024 was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNAs! ?????? ?? Without this groundbreaking discovery, MiraDX would not exist. MiraDX applies a unique class of microRNAs to personalize cancer treatment. We have developed diagnostic tests that can predict an increased risk of long-term side effects after radiation therapy for prostate cancer, and we're working on more! ?? Because microRNAs are small parts of genetic material that help control what cells do and when they do it, their discovery is advancing diagnostics and therapeutics for many diseases, such as metabolic disorders, cardiovascular disease, neurodegenerative conditions, and cancer. ??? MiraDX is proud to be part of the effort to develop microRNA-based diagnostic testing to improve cancer treatment outcomes for patients.